Chargement en cours...
Efficacy and Safety of Epidermal Growth Factor Receptor (EGFR) Inhibitors Plus Antiangiogenic Agents as First-Line Treatments for Patients With Advanced EGFR-Mutated Non-small Cell Lung Cancer: A Meta-Analysis
Background: Tyrosine kinase inhibitors (TKIs) are standard treatment options for non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations. Increasing clinical investigations have explored the value of EGFR-TKIs plus antiangiogenic drugs as the first-line treatment fo...
Enregistré dans:
| Publié dans: | Front Oncol |
|---|---|
| Auteurs principaux: | , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Frontiers Media S.A.
2020
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7344312/ https://ncbi.nlm.nih.gov/pubmed/32714857 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2020.00904 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|